Vergence/accommodative therapy for symptomatic convergence insufficiency in children: Time course of improvements in convergence function
Erin C Jenewein,Susan Cotter,Tawna Roberts,Marjean Kulp,G Lynn Mitchell,Lisa A Jones-Jordan,Angela M Chen,Kristine Hopkins,Kristine Huang,Deborah Amster,Gregory Fecho,Julie Tyler,Shivakhaami Meiyeppen,Mitchell Scheiman,Convergence Insufficiency Treatment Trial - Attention and Reading Trial (CITT-ART) Investigator Group,Jeffrey Cooper,Erica Schulman,Kimberly Hamian,Danielle Iacono,Steven Larson,Valerie Leung,Sara Meeder,Elaine Ramos,Steven Ritter,Audra Steiner,Alexandria Stormann,Marilyn Vricella,Xiaoying Zhu,Susanna Tamkins,Naomi Aguilera,Elliot Brafman,Hilda Capo,Kara Cavuoto,Isaura Crespo,Monica Dowling,Kristie Draskovic,Miriam Farag,Vicky Fischer,Sara Grace,Ailen Gutierrez,Carolina Manchola-Orozco,Maria Martinez,Craig McKeown,Carla Osigian,Tuyet-Suong Pham,Leslie Small,Natalie Townsend,Michael Gallaway,Mark Boas,Christine Calvert,Tara Franz,Amanda Gerrouge,Donna Hayden,Zachary Margolies,Jenny Myung,Karen Pollack,Ruth Shoge,Andrew Tang,Noah Tannen,Lynn Trieu,Luis Trujillo,Michelle Buckland,Allison Ellis,Jennifer Fogt,Catherine McDaniel,Taylor McGann,Ann Morrison,Shane Mulvihill,Adam Peiffer,Maureen Plaumann,Gil Pierce,Julie Preston,Kathleen Reuter,Nancy Stevens,Jake Teeny,Andrew Toole,Douglas Widmer,Aaron Zimmerman,Carmen Barnhardt,Eric Borsting,Raymond Chu,Susan Parker,Dashaini Retnasothie,Judith Wu,Richard Hertle,Penny Clark,Kelly Culp,Kathy Fraley,Drusilla Grant,Nancy Hanna,Stephanie Knox,William Lawhon,Lan Li,Sarah Mitcheff,Isabel Ricker,Casandra Solis,Palak Wall,Samantha Zaczyk,Wendy Marsh-Tootle,Michelle Bowen,Terri Call,Kristy Domnanovich,Marcela Frazier,Nicole Guyette,Oakley Hayes,John Houser,Sarah Lee,Jenifer Montejo,Tamara Oechslin,Candace Turner,Katherine Weise,Rachel Coulter,Annette Bade,Surbhi Bansal,Laura Falco,Katherine Green,Gabriela Irizarry,Jasleen Jhajj,Nicole Patterson,Jacqueline Rodena,Yin Tea,Dana Weiss,Lauren Zakaib,Ingryd Lorenzana,Yesena Meza,Ryan Mann,Mariana Quezada,Scott Rein,Indre Rudaitis,Susan Stepleton,Beata Wajs,Maryann Redford,Carolyn Denton,Eugene Arnold,Christopher Chase,Sharyl Wee,Katlynn Dahl-Leonard,Kenneth Powers,Amber Alaniz,Marie Diener-West,William V Good,David Grisham,Christopher J Kratochvil,Dennis Revicki,Jeanne Wanzek,Mustafa Abraham,Julianne Dangelo,Jordan Hegedus,Ian Jones,Alexander Junglas,Jihyun Lee,Jadin Nettles,Curtis Mitchell,Mawada Osman,Gloria Scott-Tibbs,Loraine Sinnott,Chloe Teasley,Victor Vang,Robin Varghese
DOI: https://doi.org/10.1111/opo.13062
Abstract:Purpose: To evaluate the time course of improvements in clinical convergence measures for children with symptomatic convergence insufficiency treated with office-based vergence/accommodative therapy. Methods: We evaluated convergence measures from 205, 9- to 14-year-old children with symptomatic convergence insufficiency randomised to office-based vergence/accommodative therapy in the Convergence Insufficiency Treatment Trial - Attention and Reading Trial (CITT-ART). Near-point of convergence (NPC) and near-positive fusional vergence (PFV) were measured at baseline and after 4, 8, 12 and 16 weeks of therapy; mean change in NPC and PFV between these time points were compared using repeated measures analysis of variance. Rates of change in NPC and PFV from: (1) baseline to 4 weeks and (2) 4-16 weeks were calculated. For each time point, the proportion of participants to first meet the normal criterion for NPC (<6 cm), PFV blur (break if no blur; >15Δ and >2 times the exodeviation) and convergence composite (NPC and PFV both normal) were calculated. Results: The greatest change in NPC and PFV (7.6 cm and 12.7 Δ) and the fastest rate of improvement in NPC and PFV (1.9 cm/week and 3.2 Δ/week, respectively) were both found during the first 4 weeks of therapy, with both slowing over the subsequent 12 weeks. After 12 weeks of therapy, the NPC, PFV and convergence composite were normal in 93.2%, 91.7% and 87.8% of participants, respectively, and normalised with another 4 weeks of therapy in 4.4%, 2.0% and 4.4% of participants, respectively. Conclusion: Although the greatest improvements in NPC and PFV occurred in the first 4 weeks of therapy, most participants had weekly improvements over the subsequent 12 weeks of treatment. While most children with convergence insufficiency obtained normal convergence following 12 weeks of therapy, an additional 4 weeks of vergence/accommodative therapy may be beneficial for some participants.